INNOVIVA Reports Q2 Earnings: A Snapshot

August 11, 2023

🌥️Trending News

INNOVIVA ($NASDAQ:INVA), Inc., based in California, is a biopharmaceutical company focused on the development and commercialization of therapeutic inhaled drugs for the treatment of respiratory diseases. The company recently reported its second quarter earnings, with a summary review provided by The Washington Post. The decrease was due to a decrease in royalties from its GlaxoSmithKline partnership as well as a decrease in sales from its own products. This increase was due to an increase in expenses related to its own products being offset by an increase in royalties from GlaxoSmithKline. Looking ahead, INNOVIVA is confident that its product pipeline will continue to be successful, with several new drugs currently in clinical development.

Additionally, the company is continuing to expand its pipeline and is actively seeking new partnerships to further its growth. Overall, INNOVIVA’s second quarter earnings report looks promising for investors and the future of the company. With its current product pipeline and plans for continued expansion, INNOVIVA is poised to remain a strong player in the biopharmaceutical industry.


The report showed that the company had earned a total revenue of 100.81M USD, with a net income of 88.95M USD. The figures indicate a 6.8% decrease in total revenue when compared to the same quarter of the previous year. Looking back further, INNOVIVA‘s total revenue has declined from 100.81M USD to 80.99M USD in the last three years.

This could be attributed to various economic and industry factors. It is yet to be seen how these figures will pan out in the near future.

About the Company

  • INNOVIVA_Reports_Q2_Earnings_A_Snapshot”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Innoviva. More…

    Total Revenues Net Income Net Margin
    290.42 233.35 36.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Innoviva. More…

    Operations Investing Financing
    88.45 53.32 -252.33
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Innoviva. More…

    Total Assets Total Liabilities Book Value Per Share
    1.12k 563.15 8.47
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Innoviva are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -1.0% -28.4% 98.7%
    FCF Margin ROE ROA
    30.4% 32.1% 16.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Price History

    INNOVIVA reported their Q2 earnings on Thursday, with their stock opening at $13.1 and closing at $13.2. This slight increase in price reflects the company’s solid performance this quarter. Although INNOVIVA faced many challenges, they were able to secure a steady growth to maintain their position in the market. Overall, INNOVIVA had a successful quarter in terms of earnings and stock performance.

    They have managed to remain resilient despite the tumultuous nature of the market, and this is a testament to their business strategy and commitment to their shareholders. Moving forward, INNOVIVA will continue to develop innovative products and services to ensure they stay ahead of the competition. Live Quote…


    GoodWhale has conducted an analysis of INNOVIVA‘s financials and found that based on Star Chart classification it is an elephant type company. This means that the company is rich in assets after deducting liabilities. This type of company is likely to be of interest to investors who are looking for stability and long-term returns, as well as those investing for capital gains or interested in the company’s products or services. In terms of its health score, INNOVIVA achieved a score of 9/10, indicating that the company is financially sound and capable of sustaining future operations in times of crisis. Further analysis revealed that INNOVIVA is strong in asset and profitability, medium in its growth potential, and weak in terms of dividend yield. With this mix, INNOVIVA is well-positioned for long-term success. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Some of their competitors are Kiora Pharmaceuticals Inc, Plus Therapeutics Inc, and Incyte Corp. While all these companies focus on different aspects of COPD treatment, they all share the common goal of helping patients manage their disease.

    – Kiora Pharmaceuticals Inc ($NASDAQ:KPRX)

    Kiora Pharmaceuticals Inc is a pharmaceutical company with a focus on developing treatments for rare diseases. The company has a market cap of 5.74M as of 2022 and a return on equity of -113.06%. The company’s focus on rare diseases means that it has a small potential customer base, which may limit its growth potential. However, its focus on developing treatments for rare diseases also means that it is doing important work in developing new treatments for diseases that often go untreated.

    – Plus Therapeutics Inc ($NASDAQ:PSTV)

    Parexel International Corporation is a biopharmaceutical services organization, providing a range of services to the pharmaceutical, biotechnology, and medical device industries. The company has a market cap of $14.62M and a ROE of -106.7%. Parexel is headquartered in Waltham, Massachusetts, and has offices in 41 countries around the world. The company employs over 20,000 people.

    – Incyte Corp ($NASDAQ:INCY)

    Incyte Corp is a biopharmaceutical company that focuses on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The company’s market cap as of 2022 is 17.06B with a ROE of 9.94%. Incyte’s products are used in the treatment of various cancers, including leukemia, myelodysplastic syndromes and solid tumors. The company is also involved in the development of drugs for the treatment of autoimmune diseases and inflammatory conditions.


    The earnings beat analysts’ expectations but still failed to increase investors’ confidence due to the company’s declining profits and revenue. Overall, investors should exercise caution when it comes to investing in INNOVIVA Inc., as the stock may be volatile in the near future.

    Recent Posts

    Leave a Comment